Clinical Trials Logo

Hyperuricemia clinical trials

View clinical trials related to Hyperuricemia.

Filter by:

NCT ID: NCT05496075 Completed - Uric Acid Clinical Trials

Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

Start date: August 26, 2022
Phase: Phase 4
Study type: Interventional

To clarify the uric acid-lowering efficacy of orlistat in overweight/obese patients with hyperuricemia, and to evaluate the safety of orlistat treatment

NCT ID: NCT05476627 Recruiting - Obesity Clinical Trials

Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases

Start date: July 1, 2022
Phase:
Study type: Observational

With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.

NCT ID: NCT05476367 Not yet recruiting - Arthritis Knee Clinical Trials

Patients With Asymptomatic Hyperuricemia Have Stronger Local Inflammatory Response and Worse Outcome After Total Knee Arthroplasty

Start date: August 1, 2022
Phase:
Study type: Observational

We identify all patients who had undergone primary total knee arthroplsty(TKA) from April 1, 2015, to March 30, 2016. Patients are grouped by uric acid level. The knee society score(KSS score) and the hospital for special surgery knee score (HSS score) before the surgery and 6 years after the surgery will be collected. Also the clinical data will be collected.

NCT ID: NCT05474560 Completed - Clinical trials for Non-Alcoholic Fatty Liver Disease

Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients

Start date: January 1, 2022
Phase: Phase 4
Study type: Interventional

Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver disease, and it is increasingly diagnosed in many developed and developing countries. Previous studies suggested a significant association between hyperuricemia and MAFLD and that hyperuricemia plays a causal role in the development of MAFLD. Xanthine oxidase is a key enzyme in uric acid metabolism, and It thus can be considered as is a therapeutic target for MAFLD, so long-term urate-lowering therapy may play a role in amelioration of MAFLD by controlling uric acid levels. So, this study is conducted to assess the effect of controlling hyperuricemia using different xanthine oxidase inhibitors on amelioration of MAFLD.

NCT ID: NCT05454423 Not yet recruiting - Gout Clinical Trials

Effect of Aquatic Exercise and Traditional Physical Therapy on Gout in Hypertensive Menopausal Women With Hyperuricemia

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Aquatic Exercise and traditional physical therapy are effective methods of treatment for gout and hypertension in menopausal women.

NCT ID: NCT05434858 Recruiting - Hyperuricemia Clinical Trials

Imagery as Biomarker of Gout

TIGER
Start date: September 9, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to determine whether MSU crystal deposits visualized on ultrasound and/or DECT are associated with the development of symptomatic gout (according to ACR 2015 / EULAR criteria) over 5 years in hyperuricemic individuals.

NCT ID: NCT05406830 Recruiting - Clinical trials for Asymptomatic Hyperuricemia

Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia

Start date: July 13, 2022
Phase: N/A
Study type: Interventional

hyperuricemia (HUA) is an important risk factor for various chronic diseases, such as gout, and the current treatment programs for HUA are not ideal. It is urgent to find new methods to prevent and treat HUA and to carry out early clinical intervention. Acupuncture is commonly used for the treatment of HUA, while the evidence for its efficacy is still uncertain. This clinical trial aimed to evaluate the efficacy and safety of manual acupuncture for asymptomatic HUA.

NCT ID: NCT05385003 Recruiting - Clinical trials for Subjects With Hyperuricemia

Effect of Prebiotics on Hyperuricemia

Start date: May 14, 2022
Phase: N/A
Study type: Interventional

Hyperuricemia is a major risk factor for many chronic diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of Hyperuricemia. Animal studies have demonstrated that administration of prebiotics help delay the progression of Hyperuricemia through several mechanisms. This trial aims to examine its protective effect in humans.

NCT ID: NCT05347498 Not yet recruiting - Clinical trials for Primary Gout With Hyperuricemia in Adults

A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults

Start date: April 30, 2022
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the efficacy and safety of HR091506 tablets for treatment of primary gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.

NCT ID: NCT05342285 Recruiting - Clinical trials for Cardiovascular Diseases

Flow Mediated Dilation in Association With Hyperuricemia

Start date: July 30, 2022
Phase:
Study type: Observational

Assess cardiovascular affection and subclinical atherosclerosis in patients with systemic lupus using the non invasive flow mediated dilation. evaluate the role of uric acid as independent marker of cardiovascular risk in systemic lupus patient